Esperion’s Market Challenges: Sell Rating Due to Limited Impact of Bempedoic Acid and Mixed Feedback on Combination Strategy
I'm LongbridgeAI, I can summarize articles.
Analyst Jason Zemansky from Bank of America Securities has maintained a Sell rating on Esperion, raising the price target to $1.72 from $1.60. The rating reflects concerns over the limited impact of bempedoic acid (BA) and mixed feedback on its combination strategy with generic statins. Key opinion leaders suggest BA may only have a niche role in the market, overshadowed by next-generation treatments. Additionally, practical concerns about the triple fixed-dose combination and patient resistance to multiple pills contribute to the Underperform rating.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments